Taysha Gene Therapies (NASDAQ:TSHA) Reaches New 12-Month Low – What’s Next?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA)’s share price hit a new 52-week low during trading on Wednesday. The stock traded as low as $3.55 and last traded at $3.58, with a volume of 6,115,201 shares changing hands. The stock had previously closed at $4.14.

Analyst Upgrades and Downgrades

TSHA has been the topic of a number of research reports. Citizens Jmp restated a “market outperform” rating and set a $11.00 target price on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, September 21st. Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. Wolfe Research began coverage on shares of Taysha Gene Therapies in a research report on Thursday, September 17th. They set an “outperform” rating for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, June 30th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $12.77.

Taysha Gene Therapies Trading Down 13.5%

The stock’s fifty day moving average price is $5.41 and its 200 day moving average price is $5.69. The company has a quick ratio of 17.76, a current ratio of 17.76 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.17 billion, a PE ratio of -8.52 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, sell-side analysts forecast that Taysha Gene Therapies, Inc. will post -0.52 EPS for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

Several large investors have recently bought and sold shares of TSHA. R Squared Ltd bought a new stake in Taysha Gene Therapies in the 1st quarter worth approximately $50,000. Y Intercept Hong Kong Ltd purchased a new stake in Taysha Gene Therapies in the first quarter worth about $51,000. Principal Financial Group Inc. increased its holdings in Taysha Gene Therapies by 26.2% in the 1st quarter. Principal Financial Group Inc. now owns 16,185 shares of the company’s stock worth $72,000 after acquiring an additional 3,362 shares in the last quarter. Cetera Investment Advisers raised its stake in Taysha Gene Therapies by 34.5% during the 1st quarter. Cetera Investment Advisers now owns 28,450 shares of the company’s stock worth $127,000 after acquiring an additional 7,296 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of Taysha Gene Therapies by 698.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 25,577 shares of the company’s stock valued at $141,000 after purchasing an additional 22,373 shares during the period. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus-based delivery technologies and other genetic medicine approaches to target conditions with limited or no approved treatment options.

Taysha’s research and development programs have included TSHA-102, an investigational gene therapy being developed for Rett syndrome, as well as programs for other rare neurological disorders.